search

All clinical trials

Results 460231-460240 of 470744

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV...

CMV ViremiaCMV Disease

This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options.

No longer available21 enrollment criteria

Axicabtagene Ciloleucel Expanded Access Study

Relapsed/Refractory Diffuse Large B Cell LymphomaRelapsed/Refractory Primary Mediastinal B Cell Lymphoma2 more

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of KTE-X19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Approved for marketing35 enrollment criteria

SARC021C: A Continuation Study of TH-CR-406/SARC021

Soft Tissue Sarcoma

SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.

No longer available6 enrollment criteria

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Relapsed/Refractory Hairy Cell Leukemia

Early Access Programme to provide treatment access to moxetumomab pasudotox for eligible patients with relapsed/refractory hairy cell leukemia

Approved for marketing17 enrollment criteria

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.

No longer available11 enrollment criteria

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial...

Urothelial Carcinoma

This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.

Approved for marketing24 enrollment criteria

Low-profile Visualized Intraluminal Support -HUD

Giant Wide Necked Aneurysms

The MicroVention Low-profile Visualized Intraluminal Support (LVIS*) Device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck (neck greater than or equal to 4 or a dome to neck ratio less than two), intracranial, saccular aneurysms arising from a parent vessel with a diameter of greater than or equal to 2.5mm and less than or equal to 4.5mm.

Approved for marketing1 enrollment criteria

Expanded Access Treatment Protocol CA204-143

Multiple Myeloma

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.

No longer available15 enrollment criteria

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Solid Tumors

Open-label, continuation study

No longer available9 enrollment criteria

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure...

Heart Failure With Reduced Ejection Fraction (HF-rEF)

Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.

No longer available52 enrollment criteria
1...460234602446025...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs